Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Norfolk Southern Corporation — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Norfolk Southern Corporation trades at $326.37 (market cap $72.13B). The key difference: Norfolk Southern Corporation is far larger — about 74.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Norfolk Southern Corporation pays a 1.68% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Norfolk Southern Corporation for 34 Days on average.
| MRVI | NSC | |
|---|---|---|
Market Cap | $972.90M | $72.13B |
Volume | 4,325,710 | 650,750 |
Sector | Health | Industrials |
52-Week High | $9.00 | $352.98 |
52-Week Low | $2.83 | $278.19 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $1.08B | $87.68B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Norfolk Southern (NSC) trades at $321.14, up 0.56% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (21.02% net margin). Recent news highlights momentum for the Union Pacific merger, while institutional buying and a $361.86 consensus price target suggest upside potential.
Outlook remains positive with merger progress and dividend stability, but risks include fuel cost pressures and regulatory hurdles. The current valuation (P/E 27.4) demands execution on freight share gains and merger benefits to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
